^
ALK R1209Q
Colon Cancer
crizotinib + pazopanib
Sensitive
:
C3
Onco Targets Ther - 2d
No biomarker
Colon Cancer
capecitabine
Sensitive
:
A1
No biomarker
Colon Cancer
5-fluorouracil + irinotecan
Sensitive
:
A1
No biomarker
Colon Cancer
Mvasi (bevacizumab biosimilar)
Sensitive
:
A1
No biomarker
Colon Cancer
Zirabev (bevacizumab biosimilar)
Resistant
:
A1
No biomarker
Colon Cancer
irinotecan
Sensitive
:
A1
No biomarker
Colon Cancer
Bevax (bevacizumab biosimilar)
Sensitive
:
A1
MSI-H/dMMR
Colon Cancer
CAPOX
Sensitive
:
A2
MSI-H/dMMR
Colon Cancer
FOLFOX
Sensitive
:
A2
No biomarker
Colon Cancer
oxaliplatin
Sensitive
:
A2
No biomarker
Colon Cancer
CAPOX
Sensitive
:
A2
No biomarker
Colon Cancer
FOLFOX
Sensitive
:
A2
No biomarker
Colon Cancer
cetuximab
Sensitive
:
A2
No biomarker
Colon Cancer
panitumumab
Sensitive
:
A2
No biomarker
Colon Cancer
FOLFIRI + bevacizumab
Sensitive
:
A2
No biomarker
Colon Cancer
ramucirumab
Sensitive
:
A2
No biomarker
Colon Cancer
ziv-aflibercept IV
Sensitive
:
A2
No biomarker
Colon Cancer
5-fluorouracil + oxaliplatin + leucovorin calcium
Sensitive
:
A2
No biomarker
Colon Cancer
mFOLFOX6
Sensitive
:
B
miR-31-5p underexpression
Colon Cancer
cetuximab
Sensitive
:
B
No biomarker
Colon Cancer
amlodipine/celecoxib
Resistant
:
B
ETV5 overexpression
Colon Cancer
5-fluorouracil
Resistant
:
B
No biomarker
Colon Cancer
capecitabine + oxaliplatin
Sensitive
:
B
NTRK3 fusion
Colon Cancer
larotrectinib
Sensitive
:
C1
NTRK1 fusion
Colon Cancer
larotrectinib
Sensitive
:
C1
VERI is free for non-commercial use, no login needed.
Content on this site is for research purposes only and is not intended  to be a substitute for medical advice.
For commercial access, including additional premium features, please contact us.
By using VERI, you are agreeing to our